Literature DB >> 9344758

Contractile failure in chronic doxorubicin-induced cardiomyopathy.

R J Boucek1, D A Dodd, J B Atkinson, N Oquist, R D Olson.   

Abstract

The mechanisms for the progression of the anthracycline-induced cardiomyopathy to contractile failure has not been defined. In vitro, doxorubicin (DOX) appears to modify calcium-mediated excitation-contraction coupling, which depresses cardiac contractility. This study characterizes the onset of contractile failure associated with the development of DOX-induced cardiomyopathy. Rabbits were treated with DOX (1 mg/kg i.v. twice weekly, 12-18 doses; DOX-treated group) and compared with a pair-fed Control group infuse with saline vehicle. The severity of the cardiomyopathy was determined by numerically-scored histopathology. Myocardial contractility was determined in thin fiber bundles from right ventricular (RV) papillary muscles and left atria that were removed and mounted on a force transducer in oxygenated Krebs-bicarbonate buffer (pH=7.4 at 30 degrees C) to record the amplitude (DT) and maximum rate (+dT/dt ) of isometric tension. Myofibrillar and calcium loading properties were determined by the calcium and caffeine-activated tension responses respectively in chemically-permeabilized fibers. With the onset of the cardiomyopathy (score <2) DT at low frequency (0.5 Hz) was depressed (0.61+/-0.01 mN/mg; n=14) compared to Control (0.93+/-0.09 mN/mg; n=15). Contractility at higher rates (1 Hz) was not different in this DOX-treated and Control groups. Maximum calcium and caffeine-activated force and the pCa to half-maximum force of permeabilized fibers were comparable in DOX-treated and Control groups. The loss of contractility of the DOX-treated group was related to reduction in sarcoplasmic reticulum calcium release channel density, as determined by Bmax for 3H-ryanodine binding in cardiac microsomal membrane fraction. Post-rest potentiation of contractility, as well as frequency-dependent (0.25-1.5 Hz) and post-extrasystolic potentiation of contractility were preserved in the DOX-treated group. In vitro, DOX depressed post-rest potentiation of contractility. Thus, the onset of contractile failure of the DOX-induced cardiomyopathy is characterized by effects consistent with disordered calcium-mediated excitation-contraction coupling and these effects are qualitatively different than in vitro effects of DOX. Copyright 1997 Academic Press Limited.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9344758     DOI: 10.1006/jmcc.1997.0494

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  7 in total

1.  Berberine sensitizes mutliple human cancer cells to the anticancer effects of doxorubicin in vitro.

Authors:  Nannan Tong; Jie Zhang; Youran Chen; Zhubo Li; Yonghuang Luo; Hua Zuo; Xiaoyan Zhao
Journal:  Oncol Lett       Date:  2012-03-14       Impact factor: 2.967

2.  Cardioprotective effects of sodium thiosulfate against doxorubicin-induced cardiotoxicity in male rats.

Authors:  Maryam Shekari; Narges Khalilian Gortany; Mina Khalilzadeh; Alireza Abdollahi; Homanaz Ghafari; Ahmad Reza Dehpour; Mahmoud Ghazi-Khansari
Journal:  BMC Pharmacol Toxicol       Date:  2022-05-25       Impact factor: 2.605

3.  Unbalanced upregulation of ryanodine receptor 2 plays a particular role in early development of daunorubicin cardiomyopathy.

Authors:  Dana Kucerova; Gabriel Doka; Peter Kruzliak; Katarina Turcekova; Jana Kmecova; Zuzana Brnoliakova; Jan Kyselovic; Uwe Kirchhefer; Frank U Müller; Peter Krenek; Peter Boknik; Jan Klimas
Journal:  Am J Transl Res       Date:  2015-07-15       Impact factor: 4.060

4.  Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A.

Authors:  Amy D Hanna; Alex Lam; Steffi Tham; Angela F Dulhunty; Nicole A Beard
Journal:  Mol Pharmacol       Date:  2014-08-08       Impact factor: 4.436

5.  Doxorubicin-Conjugated Zinc Oxide Nanoparticles, Biogenically Synthesised Using a Fungus Aspergillus niger, Exhibit High Therapeutic Efficacy against Lung Cancer Cells.

Authors:  Prakriti Mishra; Afza Ahmad; Lamya Ahmed Al-Keridis; Nawaf Alshammari; Nadiyah M Alabdallah; Khursheed Muzammil; Mohd Saeed; Irfan Ahmad Ansari
Journal:  Molecules       Date:  2022-04-18       Impact factor: 4.927

6.  Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions.

Authors:  Jason T Anderson; Kevin M Huang; Maryam B Lustberg; Alex Sparreboom; Shuiying Hu
Journal:  Rev Physiol Biochem Pharmacol       Date:  2022       Impact factor: 7.500

7.  Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.

Authors:  Umesh Chaudhari; Harshal Nemade; Vilas Wagh; John Antonydas Gaspar; James K Ellis; Sureshkumar Perumal Srinivasan; Dimitry Spitkovski; Filomain Nguemo; Jochem Louisse; Susanne Bremer; Jürgen Hescheler; Hector C Keun; Jan G Hengstler; Agapios Sachinidis
Journal:  Arch Toxicol       Date:  2015-11-04       Impact factor: 5.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.